According to the IMARC Group, the cancer pain market reached a value of US$ 1,717.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2,523.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.56% during 2024-2034. This can be attributed to the increasing utilization of nerve blocks for treating acute and chronic pain since they provide targeted and immediate relief by directly blocking the transmission of pain signals from the damaged nerves.

Cancer pain represents a medical condition related to different oncology disorders in which there's a complex, unpleasant sensation that reflects damage to the body and the body's reaction to the injury. The cancer pain market is experiencing significant growth, driven by the rising incidence of the disease and the increasing emphasis on palliative care. Besides this, pharmacological advancements play a crucial role in this field, with opioid analgesics such as fentanyl remaining the cornerstone of disease management, thereby catalyzing the cancer pain market expansion.The development of novel non-opioid therapies, including cannabinoids and NMDA receptor antagonists, is gaining traction as they offer alternative options with reduced risk of addiction and side effects.

Request for a sample of this report: https://www.imarcgroup.com/cancer-pain-market/requestsample

Countries Covered:

• United States

• Germany

• France

• United Kingdom

• Italy

• Spain

• Japan

This report also provides a detailed analysis of the current Cancer Pain Market and late-stage pipeline .

In-Market :

• Drug Overview

• Mechanism of Action

• Regulatory Status

• Clinical Trial Results

• Drug Uptake and Market Performance

Late-Stage Pipeline:

• Drug overview

• Mechanism of action

• Regulatory status

• Clinical trial results

• Drug uptake and market performance

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/cancer-pain-market

Competitive Landscape with key players:

The competitive landscape of the Cancer Pain Market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Kyowa Kirin International

2. Orexo

3. CIS bio internationa

4. BTcP Pharma/Pharmbio Korea

5. GW Pharmaceuticals

6. Tetra Bio-Pharma

7. Sorrento Therapeutics

8. Aphria/Medlab

9. WEX Pharmaceuticals

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145